Technical Intelligence & Insights
Dive into our comprehensive technical reports covering the Pharma Healthcare sector. We analyze novel patents, catalytic processes, and cost-reduction strategies to streamline your commercial manufacturing.
Novel 5-step synthesis of KRAS G12D inhibitor intermediate 1 from L-proline. Reduces cost and complexity compared to ozonolysis routes.
Patent CN102070490B reveals a novel route for fexofenadine intermediates, offering high purity and significant cost reduction in API manufacturing for global supply chains.
Patent CN115894503A details a streamlined 5-step synthesis of a key pyrrolizine intermediate from L-proline, offering significant cost reduction and safer processing for API manufacturing.
Patent CN108912055B details a catalytic asymmetric dihydroxylation route for antiviral intermediates, offering cost-effective and scalable manufacturing solutions for global supply chains.
Patent CN113754600A reveals a safer, cost-effective route for 1,4-diazaspiro[5,5]undecan-3-one, eliminating toxic reagents for reliable pharmaceutical intermediate supply.
Patent CN111170924B reveals a mild electrochemical route for fluorinated indoles, offering cost-effective scale-up for pharmaceutical intermediates.
Patent CN112552184B reveals a scalable 4-step synthesis for cyclopropyl chiral amines, offering significant cost reduction and high purity for pharmaceutical manufacturing.
Novel synthesis method for Bortezomib intermediates ensures high purity and cost efficiency. Reliable supply chain for pharmaceutical manufacturing partners seeking scalable solutions.
Patent CN110903189B details a cost-effective copper-catalyzed route for chiral 2-aryl propionates, offering significant supply chain advantages for NSAID intermediate manufacturing.
Patent CN102633802B details a scalable 3-step route for 2-chloro-7H-pyrrolo[2,3-d]pyrimidine, offering significant cost reduction and simplified purification for API manufacturing.
Patent CN112047829B reveals a cost-effective Grignard carboxylation route for high-purity Alectinib intermediates, offering significant supply chain advantages.
Novel patent CN108623577A offers high-yield Amonebvir intermediate synthesis. Reduces steps, avoids protecting groups, ensures supply chain stability for pharmaceutical manufacturing.
Patent CN112047829B reveals a cost-effective Grignard carboxylation route for high-purity Alectinib intermediates, offering significant supply chain advantages.
Novel one-pot synthesis for Montelukast Sodium ensures high purity and yield. Ideal for reliable API intermediate suppliers seeking cost-effective manufacturing solutions.
Patent CN104402790A reveals a safer Ezetimibe route. Eliminating silyl protection reduces toxicity and cost for reliable API intermediate supply.
Advanced manufacturing route for Vilazodone intermediates utilizing microwave cyanation and efficient piperazine cyclization, offering high purity and scalable production for pharmaceutical supply chains.
Patent CN117304194B details a safer Upadacitinib synthesis route. Achieve high purity and cost reduction in pharma manufacturing with scalable intermediates.
Patent CN117304194B details a safer high-yield route for JAK inhibitor production reducing hazardous reagents and enhancing supply chain stability for global procurement.
Patent CN107778271A details a scalable CX1409 synthesis avoiding chromatography. This method offers significant cost reduction and supply chain reliability for global buyers.
Novel diclazuril preparation method eliminates chromatography steps ensuring high purity and supply chain reliability for veterinary drug manufacturing partners globally.